Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$5.71
-2.5%
$6.03
$3.93
$7.32
$290.85M1.51699,431 shs457,210 shs
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$13.73
-5.2%
$12.58
$8.04
$25.88
$372.34M2.27418,348 shs119,673 shs
GENPREX stock logo
GNPX
GENPREX
$0.29
-1.7%
$0.28
$0.20
$3.97
$9.48M-0.54.16 million shs438,586 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$11.97
-3.2%
$12.65
$5.76
$27.38
$150.20M0.43156,128 shs124,359 shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.27
$1.37
$1.12
$2.55
$62.29M0.436,382 shs13,431 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
+0.34%-0.91%-9.44%+27.17%+17.23%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-2.10%+6.20%+12.25%+49.28%-33.36%
GENPREX stock logo
GNPX
GENPREX
+2.76%+10.61%-8.95%+9.16%-84.36%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-5.28%-1.24%-1.67%-12.52%+106.86%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%+0.79%-9.93%-5.22%-7.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.8147 of 5 stars
3.51.00.04.51.82.50.0
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
1.9359 of 5 stars
3.60.00.00.01.42.50.6
GENPREX stock logo
GNPX
GENPREX
1.118 of 5 stars
0.04.00.04.70.00.00.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.3053 of 5 stars
3.50.01.72.73.32.51.3
MediciNova, Inc. stock logo
MNOV
MediciNova
1.4705 of 5 stars
3.82.00.00.00.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
3.00
Buy$19.25237.42% Upside
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$54.00293.44% Upside
GENPREX stock logo
GNPX
GENPREX
0.00
N/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50154.72% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00451.18% Upside

Current Analyst Ratings Breakdown

Latest LFVN, MNOV, ARCT, ABEO, and GNPX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
6/2/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/16/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$21.00 ➝ $20.00
5/15/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
4/30/2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
$3.50M83.39N/AN/A$1.01 per share5.65
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$131.27M2.84N/AN/A$8.90 per share1.54
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/A$0.15 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.75$0.81 per share14.81$2.05 per share5.84
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/A$1.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)
GENPREX stock logo
GNPX
GENPREX
-$21.11MN/A0.00N/AN/AN/A-664.65%-370.18%8/8/2025 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6917.29N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)

Latest LFVN, MNOV, ARCT, ABEO, and GNPX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025N/A
GENPREX stock logo
GNPX
GENPREX
-$0.71N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.11N/AN/AN/A$17.64 millionN/A
5/15/2025Q1 2025
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
-$0.35-$0.24+$0.11-$0.24N/AN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/12/2025Q1 2025
GENPREX stock logo
GNPX
GENPREX
-$0.82-$0.26+$0.56-$0.26N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
N/AN/AN/AN/AN/A
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$0.715.21%N/AN/A N/A
GENPREX stock logo
GNPX
GENPREX
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.50%N/A26.09%3 Years
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A

Latest LFVN, MNOV, ARCT, ABEO, and GNPX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
0.27
4.90
4.90
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.06
5.64
5.64
GENPREX stock logo
GNPX
GENPREX
N/A
1.94
1.94
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66

Institutional Ownership

CompanyInstitutional Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
80.56%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
GENPREX stock logo
GNPX
GENPREX
14.05%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%

Insider Ownership

CompanyInsider Ownership
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
6.90%
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
16.60%
GENPREX stock logo
GNPX
GENPREX
8.47%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Abeona Therapeutics Inc. stock logo
ABEO
Abeona Therapeutics
9051.16 million47.63 millionOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.62 millionOptionable
GENPREX stock logo
GNPX
GENPREX
2033.15 million30.34 millionNo Data
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable

Recent News About These Companies

MediciNova says first patient enrolled in EAP trial to evaluate MN-166
MediciNova Inc.
MediciNova provides update in letter to stockholders
MediciNova granted Notice of Allowance for MN-001 patent by USPTO

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abeona Therapeutics stock logo

Abeona Therapeutics NASDAQ:ABEO

$5.70 -0.15 (-2.48%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$13.72 -0.76 (-5.21%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

GENPREX stock logo

GENPREX NASDAQ:GNPX

$0.29 0.00 (-1.68%)
As of 03:29 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$11.97 -0.40 (-3.20%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.27 0.00 (0.00%)
As of 03:33 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.